Donate

Home2

CANCERX DEPLOYS A NEW APPLICATION OF A WELL-ESTABLISHED
FINANCE MECHANISM TO FUND HUMAN PHASE CLINICAL CANCER RESEARCH

CanceRx Mission

The CanceRx mission is to accelerate clinical phase cancer research and FDA approvals by synchronizing finance with the speed of science to achieve more effective therapies capable of producing long and meaningful remission with good quality of life and affordable costs.

What Is CanceRx

CanceRx deploys a new application of a well-established finance method
to fund human-phase clinical cancer research.

Structures a diversified portfolio of highly selective promising clinical phase cancer therapeutics
Accelerates the delivery of targeted, more effective personalized cancer treatments for patients
Leverages high-impact charitable giving with the utilization of long-term bond financing to match the speed of science

What Makes CanceRx Different

  • Diverts from the traditional single shot on goal, one-size-fits-all approach to cancer treatments.
  • Invests in a highly scrutinized, diversified portfolio of cancer therapeutics designed to achieve higher probabilities of success for patients.
  • Adopts a funding mechanism of long-run bond-financing rather than the short-run, high-cost usage of private equity financing — matching the financing to the speed of science.
  • Drives patient outcomes over commercial profits.
  • Provides a structure for an IRS approved, wholly owned downstream for-profit subsidiary to generate a continuous flow of substantial revenues back to the foundation.
  • Returns profits to the CanceRx Foundation to continue to further cancer clinical research.
  • Creates a high-impact “Evergreen” funding approach to accelerate cancer therapeutics and diagnostics from bench-to-bedside application.

In the News

Posted on

Bonds Have Been Awful. It’s a Good Time to Buy.

It’s impossible to survey the current bond market without shuddering. A team of analysts at Bank of America calls it “the greatest bond bear market of all time.”

Fixed-income investors have been experiencing calamitous price declines in the bond market since summer 2020. Some 30-year U.S. Treasuries have lost 50 percent of their value, the Bank of America team noted.

As interest rates have risen over the past few years, breathtaking price movements have been occurring with dismaying frequency. And as losses have mounted, it’s been easy to give up on bonds.

But if you have lost your taste for them — or have never owned them at all — I still believe that investment-grade bonds are worthwhile for many, if not all, investors. In fact, the higher yields and lower prices in the market today mean that this is an excellent time to buy bonds.

For most people, the easiest way to do this is through a broad low-cost mutual fund or exchange-traded fund. Bonds make sense because, despite their recent problems, they still have traditional virtues.

 

Read More
Read More
Posted on

Pfizer Inks Potential $7B Deal with Flagship to Deepen Pipeline

Pfizer is looking to enrich its pipeline with up to 10 new innovative medicines by partnering with startup creator Flagship Pioneering, the companies announced Tuesday.

Under the terms of the agreement, Pfizer and Flagship will each contribute an upfront investment of $50 million. The collaboration will leverage Flagship’s rich ecosystem of biotechnology platforms and more than 40 human health companies.

Read More
Read More
Posted on

Harvard Business School Announces Its 2022-2023 Blavatnik Fellows

BOSTON—Harvard Business School (HBS) has named its 2022-23 Blavatnik Fellows and the program’s ninth cohort. Launched in 2013, the Blavatnik Fellowship in Life Science Entrepreneurship is part of a gift to Harvard University from the Blavatnik Family Foundation. This program supports HBS alumni and Harvard-affiliated postdocs as they build their promising life science ventures by developing their leadership talents and providing mentorship and community during their entrepreneurial journey.

Read More
Read More
Posted on

Eye-catching cancer drug trial results have researchers asking: What’s next?


After a small cancer drug study yielded the unprecedented result of 100 percent of participants entering remission, oncologists — and patients — wonder if the approach from the experimental drug trial can apply to other types of cancer.





The study out of Memorial Sloan Kettering Cancer Center in New York has oncologists excited over the prospect that immunotherapy, the treatment type used in the trial, has increasingly shown effectiveness — without surgery




Read More
Read More
Posted on

New blood test could change the way cancer is detected


GRAIL, a Silicon Valley startup, created the Galleri test, which can screen for more than 50 cancers by looking at blood for DNA shed by cancer tumors. If it sees that DNA, then it predicts where the cancer is. A positive result isn’t always accurate, but researchers at the National Cancer Institute say study results so far could potentially revolutionize cancer screening, and they’re designing bigger studies.




Read More
Read More

You Can Donate to the CanceRx Foundation

According to the National Cancer Institute (NCI), there are as many as 20,000 potentially life-saving basic cancer therapy patents, which due to enormous cost and high attrition rates remain dormant.

CanceRx is dedicated to multiplying the probability of success by increasing the number of projects funded through the critical human clinical trial stage with scale, diversification, and the new application of finance.



Copyright © 2024 CanceRx. All rights reserved.